GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (LTS:0AAJ) » Definitions » Current Deferred Revenue

PolyPeptide Group AG (LTS:0AAJ) Current Deferred Revenue : CHF0.0 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

PolyPeptide Group AG's current deferred revenue for the quarter that ended in Jun. 2024 was CHF0.0 Mil.

PolyPeptide Group AG Current Deferred Revenue Historical Data

The historical data trend for PolyPeptide Group AG's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Current Deferred Revenue Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

PolyPeptide Group AG Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.

PolyPeptide Group AG Headlines

No Headlines